within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01C_AgentsAgainstLeishmaniasisAndTrypanosomiasis.P01CA03_Fexinidazole;

model Fexinidazole
  extends Pharmacolibrary.Drugs.ATC.P.P01CA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Fexinidazole</td></tr><tr><td>ATC code:</td><td>P01CA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fexinidazole is an oral nitroimidazole-based medication indicated for the treatment of human African trypanosomiasis (sleeping sickness), caused by Trypanosoma brucei gambiense. It is the first all-oral regimen for this disease and was approved by the European Medicines Agency and WHO for this indication. It is used in both first and second stage disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration of fexinidazole in adult patients with sleeping sickness. Parameters are based on PopPK modeling in infected individuals (adults) from a phase II/III clinical study.</p><h4>References</h4><ol><li><p>Burrell-Saward, H, et al., &amp; Croft, SL (2017). Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. <i>International journal of antimicrobial agents</i> 50(2) 203–209. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2017.01.038\">10.1016/j.ijantimicag.2017.01.038</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28552771/\">https://pubmed.ncbi.nlm.nih.gov/28552771</a></p></li><li><p>Tarral, A, et al., &amp; Strub-Wourgaft, N (2014). Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. <i>Clinical pharmacokinetics</i> 53(6) 565–580. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0136-3\">10.1007/s40262-014-0136-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24535888/\">https://pubmed.ncbi.nlm.nih.gov/24535888</a></p></li><li><p>Watson, JA, et al., &amp; White, NJ (2019). Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. <i>Antimicrobial agents and chemotherapy</i> 63(4) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02515-18\">10.1128/AAC.02515-18</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30670439/\">https://pubmed.ncbi.nlm.nih.gov/30670439</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fexinidazole;
